An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Trial Profile

An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 31 May 2017 Status changed from active, no longer recruiting to completed.
    • 16 Mar 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017, according to ClinicalTrials.gov record.
    • 16 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top